Early-phase trials targeting HER2-positive gastric cancer and EGFR-expressing non-small-cell lung cancer showed partial responses and temporary disease stabilisation, with progression-free survival typically limited to a few months [117,118]. The gene discussed is EGFR; the disease is gastric cancer.